-
2024 LIMS Trends
The laboratory information management system (LIMS) landscape in 2024 is a dynamic one, driven by accelerating advancements in technology and evolving industry needs. This article shares the four key trends.
-
The Power Couple: CRISPR And Oligonucelotides
Drug design using CRISPR depends on long guide RNA (gRNA) sequences. Find out how this love match between long oligos and CRISPR works.
-
Five Essentials For Accurate Oligonucleotide Chemistry
Explore five key areas in oligonucleotide chemistry where improvements will have a huge influence on your synthesis quality.
-
A New Reality In Life Sciences
Gain insight from this author's experience with virtual reality (VR) and the specific benefits of VR in scientific contexts.
-
Big Risks Yield Great Rewards In Cell Therapy
George White, Cytiva’s GM of Product Management for Cell and Gene Therapy, provides insight into the latest developments and strategies in cell therapy and where this dynamic field is headed.
-
Finding The Talent To Fuel Biopharma Breakthroughs
Explore findings from research into talent pool resilience in the biopharmaceutical industry that incorporate survey insights as well as external data to ensure a more accurate overview.
-
Impact Of Glycosylation On The Effector Functions Of Monoclonal Antibodies
In an example using rituximab and its biosimilars, explore the significance of minor differences of glycosylation in antibodies and its impact on their properties and functionality.
-
Impact Of Immunogenicity On Efficacy And Safety Of Biosimilars
The presence of anti-drug antibodies (ADAs) can affect the effectiveness and safety of biologic drugs. Read why regulatory agencies emphasize the need for extensive immunogenicity evaluation in biosimilar development.
-
Metabolite And Nutrient Analysis As Crucial Components For Optimal Upstream Process
Discover how insights into cell metabolism can further enable the development of efficient cell culture processes through tailored nutrient supplementation and monitoring.
-
Development And Regulation Of Veterinary Monoclonals
Although veterinary mAbs have achieved commercial success, ongoing discussions and clinical developments surrounding them are expected to outline a clear regulatory pathway in the near future.
-
The Latest Trends In The Prevention And Treatment Of Cervical Cancer
Unearth what immune checkpoint inhibitors are showing promise in treating cervical cancer and how advancements in these treatments paired with additional prevention strategies are improving patient outcomes.
-
Novel Approaches For Obtaining High-productivity Clones
Let's dig into cell line selection approaches, transposons to increase copy number for the gene of interest, and targeted integration to rapidly obtain high-productivity clones.
-
Lowering The Lipids Barrier: The Key To Accelerating RNA-LNP Drug Development
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Getting CMC Right For Emerging Technologies
Establishing a chemistry, manufacturing, and controls strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics.
-
Pacesetters Are Product Innovators Who Embrace Digital Process Enhancement
The Josh Bersin Company recently underwent research examining pharma/biotech “pacesetters” in the field. We caught up with Jordan Schmitting, senior research analyst at The Josh Bersin Company, to discuss the trends illuminated by the research.
-
Following The Science To Develop Best-In-Class Cancer Drugs
As innovative cancer therapeutics continue to enter the clinical trial pipeline, some developers are shifting their focus towards developing drugs that are safe and efficacious with minimal toxicity.
-
A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments
No two journeys through the drug pipeline are the same; the ability to leverage a variety of approaches for different products is what sets one lean biotech company apart.
-
A Tale Of Two Brothers: The Abpro Founders
By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.
-
Welcoming The “Era Of ADCs”
Dr. Loretta Itri sat down to explore the promise of TRODELVY®️ and other antibody-drug conjugates as transformative treatments for a range of malignancies and intractable diseases.
-
Trends In Next-Generation Delivery Technologies
Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.
-
Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
Legal And IP Protection For New Biotechs
Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs.
-
How To Develop A Scalable AAV Process, From Start To Finish
Get highlights from a developed process that has been – and continues to be refined – by Cytiva scientists. These insights are framed around common challenges in AAV development and production.
-
Improving The Characterization Of Gene Therapy Products
The analysis of over 10 variant callers and other bioinformatics tools for viral variant detection are discussed to better understand how the outcomes can improve gene therapy product characterization.
-
Preformulation Of Excipients In Biologics Development
Most of the instability problems of a drug product come from excipients, in particular, they come from impurities in excipients. Those issues are best cleaned up in the preformulation period to determine excipient compatability.
-
COGs Process Economics For Autologous Cell Therapy
Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and additional insights. Discover how cell therapy manufacturers can combat these costs.
-
Determining RNA Integrity And Purity By Capillary Gel Electrophoresis
To ensure mRNA product quality, it's important to confirm the integrity of the RNA. Examine the results of a study challenging the performance of the CGE method in assessing mRNA integrity and purity.
-
Lipid Nanoparticle Compositional Analysis By UHPLC-CAD
Explore results generated from an internal study using a proprietary mRNA-LNP formulation and UHPLC-CAD, a powerful technique for the analysis of compounds that do not contain chromophores.
-
Establishing Analytical Methods For mRNA-Based Therapies
Here, we provide a detailed description of assays for sequence identification and LNP composition in mRNA-LNP products that support the development of safe and effective mRNA therapies.
-
The Global Market For Generic Sterile Injectables To Double In Value By 2032
According to new analysis at insightSLICE, the global generic sterile injectable market size was estimated to be $79.95 billion in 2022 and is expected to grow to reach $159 billion by 2032. What are the key factors and trends driving this growth? This author shares the key data-led insights.
BIOSIMILAR DEVELOPMENT NEWS
- Phase 3 Clinical Trial Completed In China For Boan Biotech’s Dulaglutide Injection BA5101. BLA To Be Filed Soon
- Biosimilars Forum Urges Congress To Support Free Market Competition And Lower Prescription Drug Prices For Patients By Reforming Pharmacy Benefit Managers
- Celltrion USA Completes Submission Of Biologics License Application (BLA) To U.S. FDA For CT-P39, An Interchangeable Biosimilar Candidate Of XOLAIR® (omalizumab)
- Samsung Bioepis Presents Two Abstracts For Its Immunology Portfolio At The 2024 American Academy Of Dermatology (AAD) Annual Meeting
- Fresenius Kabi’s Biosimilar Tyenne (tocilizumab-aazg) Becomes The First IV And Subcutaneous Tocilizumab Biosimilar Approved By The FDA
- The Cigna Group Raises Long-Term Growth Target, And Launches New Innovative Solutions At 2024 Investor Day
- Sandoz Receives FDA Approval For First And Only Denosumab Biosimilars
- WEZLANA™ (Ustekinumab), A Biosimilar To Stelara®, Now Available In Canada For Certain Chronic Inflammatory Diseases